The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 2015 ACR/ARHP Annual Meeting: Role of Tumor Necrosis Factor Cytokines in Autoimmune Diseases Examined

2015 ACR/ARHP Annual Meeting: Role of Tumor Necrosis Factor Cytokines in Autoimmune Diseases Examined

February 16, 2016 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF
For patients with autoimmune disease, the research to date shows that the TNF-family cytokine TL1A and its receptor DR3 may be pathogenic.

For patients with autoimmune disease, the research to date shows that the TNF-family cytokine TL1A and its receptor DR3 may be pathogenic.
Image Credit: Alexander Raths/shutterstock.com

SAN FRANCISCO—To date, evidence on the efficacy of blocking the cytokine tumor necrosis factor (TNF) and its receptors in autoimmune diseases has resulted in the approval by the Food and Drug Administration (FDA) of five anti-TNF agents. Less well known, according to Richard Siegel, MD, PhD, chief, Immunoregulation Section, Autoimmunity Branch, and Clinical Director, NIAMS, National Institutes of Health, Bethesda, Md., are 17 other cytokines genetically and structurally related to TNF that comprise the TNF superfamily and play a significant role in autoimmune diseases. Each of these cytokines, along with each cytokine receptor, play a different role in disease activation, and ongoing research is looking at how these cytokines work alone or in combination in the pathogenesis of autoimmune diseases to further uncover potential therapeutic targets.

You Might Also Like
  • 2015 ACR/ARHP Annual Meeting: T Follicular Helper Cells Emerge as Potential Treatment Target for Autoimmune Diseases
  • 2015 ACR/ARHP Annual Meeting: Metabolic Pathways Linked with Inflammatory Diseases
  • 2015 ACR/ARHP Annual Meeting: Macrophage Polarization and Its Role in Inflammatory Disease
Explore This Issue
February 2016
Also By This Author
  • Study Assesses the Role of Genetics & the Gut in Reactive Arthritis

In the session, Tumor Necrosis Factor (TNF) and Beyond: The TNF-Tumor Necrosis Factor Receptor Cytokine Superfamily From Bench to Bedside, at the 2015 ACR/ARHP Annual Meeting, a panel of experts talked about the biology and therapeutic relevance of the tumor necrosis factor receptor (TNFR) family ligands and receptors to rheumatology. Among the talks were presentations on specific cytokines, TL1A and OX40L, and evidence on their role in pathogenesis of autoimmune diseases and early data on potential targets for therapy.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Cytokine TL1A & Receptor DR3

Dr. Siegel opened the session by describing the current research on TL1A and its receptor, DR3.

Dr. Siegel

Dr. Siegel

Past research has shown that TNF cytokines share very specific functions and that many mutations linked to these shared functions are linked to diseases. Importantly, he said that 32 of 98 genes encoding these shared functions of TNF cytokines (TNFSF) and their receptors (TNFSRSF) are associated with at least one autoimmune disease.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Thus, blockade of TNF cytokine signaling may provide a successful therapeutic strategy.

Toward that ultimate goal, he talked about current and ongoing research on the specific cytokine, TL1A, also known as TNFSF15.1 For patients with autoimmune disease and, particularly those with rheumatic disease, he said the research to date shows that the TNF-family cytokine TL1A and its receptor DR3 may be pathogenic.

From mouse models, the research shows that TL1A is a co-stimulator of lymphocyte activation and is essential for the development of mouse models of various autoimmune diseases, including rheumatoid arthritis, multiple sclerosis, inflammatory bowel disease and asthma, he said.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 | Single Page

Filed Under: Conditions, Meeting Reports Tagged With: 2015 ACR/ARHP Annual Meeting, American College of Rheumatology, Autoimmune disease, Cytokines, Research, rheumatology, role, therapy, TNF, tumor necrosis factorIssue: February 2016

You Might Also Like:
  • 2015 ACR/ARHP Annual Meeting: T Follicular Helper Cells Emerge as Potential Treatment Target for Autoimmune Diseases
  • 2015 ACR/ARHP Annual Meeting: Metabolic Pathways Linked with Inflammatory Diseases
  • 2015 ACR/ARHP Annual Meeting: Macrophage Polarization and Its Role in Inflammatory Disease
  • 2015 ACR/ARHP Annual Meeting: Stroke Risk Elevated after Herpes Zoster Infection Among Patients with Autoimmune Disease

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)